© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Inflammation in people with HIV is associated with cardiovascular disease and other serious health conditions.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
Las Vegas resident Stella Armstrong cured her hep C and the joy-killing fatigue and pain that came with it.
A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
The placebo-controlled trial Phase III trial of selonsertib had sought to improve fibrosis while not worsening NASH.
In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.
Researchers believe this genetic mutation protected against the 14th century-bubonic plague.
Direct-acting antivirals lower this risk to a greater extent than interferon-based regimens.
This is according to the large randomized controlled START trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
